Adalimumab (Humira) Receives FDA Approval
The U.S. Food and Drug Administration (FDA) approved Humira (adalimumab, previously D2E7) for the reduction in signs and symptoms and the inhibition of structural damage in adults with moderately to severely active rheumatoid arthritis who have failed one or more DMARDs. Humira is a human monoclonal antibody that specifically blocks tumor necrosis factor alpha (TNF-a). (read more about TNF inhibitors)
Approval of Humira from the European Agency for the Evaluation of Medicinal Products (EAEM) is currently under review.